Sunshine Heart (NASDAQ:CHFS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The brokerage currently has a $4.25 price objective on the stock. Zacks Investment Research‘s target price suggests a potential upside of 12.14% from the stock’s previous close.

According to Zacks, “CHF Solutions, Inc. is a medical device company which focused on commercializing the Aquadex FlexFlow (R) System. Its commercial product Aquadex system, is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions Inc., formerly known as Sunshine Heart Inc., is headquartered in Minneapolis. “

Separately, ValuEngine upgraded Sunshine Heart from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 31st.

Shares of Sunshine Heart (NASDAQ:CHFS) traded down $0.28 on Wednesday, reaching $3.79. The company’s stock had a trading volume of 567,300 shares, compared to its average volume of 173,046. Sunshine Heart has a 12 month low of $3.60 and a 12 month high of $576.00.

In related news, major shareholder Ki Yong Choi bought 78,211 shares of the company’s stock in a transaction on Wednesday, September 13th. The stock was bought at an average cost of $0.64 per share, with a total value of $50,055.04. Following the completion of the acquisition, the insider now owns 1,731,464 shares in the company, valued at approximately $1,108,136.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/12/06/zacks-investment-research-upgrades-sunshine-heart-chfs-to-buy.html.

Sunshine Heart Company Profile

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Get a free copy of the Zacks research report on Sunshine Heart (CHFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunshine Heart Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart Inc and related companies with MarketBeat.com's FREE daily email newsletter.